

ORIGINAL RESEARCH ARTICLE


A CONVENIENT SYNTHESIS OF 3-ARYL-5-HYDROXYALKYL-1,2,4-OXADIAZOLES FROM α -HYDROXY ESTERS AND AMIDOXIMES UNDER SOLVENT-FREE CONDITIONS

ABSTRACT

The present study aimed to synthesis and characterization of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles (5a-d, 6a-d, 7a/d, 8a-d and 9a-c). The 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles were synthesized by treatment of arylamidoxime 1a-d with α -hydroxy esters for 4 hours without any solvent and in the absence of a base. The reaction was monitored by thin layer chromatography (TLC). The heterocycles 5a-d, 6a-d, 7a/d, 8a-d and 9a-c were obtained in moderate and good yields (16-76%). The minor yield of the product (16-55%) probably due to the steric hindrance. The presences of electron-withdrawing and electron-donating groups attached to the *para* position of arylamidoximes were well tolerated by the reaction. The products were characterized by IR, ^1H and ^{13}C NMR spectroscopy and all compounds were in full agreement with the proposed structure. For instance, IR absorptions at 1593 (C=N) and 1473 cm^{-1} (C=O) were obtained for 3-phenyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (5a). ^1H NMR spectra showed absorption of methine proton of C-OH at δ 5.16. Signals of the methyl groups for 5a-d appeared as doublets at 1.69 ppm ($J = 6.6$ Hz). The characteristic signals for NCO and NCN in ^{13}C NMR at 180.9 and 168.1 ppm further identified oxadiazole moiety in 5a. With respect to compounds 6a-d the ^1H NMR spectra showed a triplet at 5.33 ppm ($J = 4.5$ Hz) for methine proton and a doublet at 3.71 ppm ($J = 4.5$ Hz) for the methylene groups. The compounds 8a-d showed a singlet at 3.76 ppm due to methyl groups of ester groups. Signals of the CH protons for 7ad appeared as singlet at 6.93 and 5.50 ppm. All other proton signals are observed in their usual resonance areas. On the other hand, the compounds 8a-d showed a singlet at 3.76 ppm due to methyl groups of ester groups. Additionally, the *in silico* study indicated that all synthesized compounds have a low risk of chronic toxicity and can be administered orally.

Keywords: Amidoxime; 1,2,4-oxadiazoles; α -hydroxy esters; solvent-free.

GRAPHICAL ABSTRACT




THIS WORK DESCRIBES A SYNTHESIS OF 3-ARYL-5-HYDROXYALKYL-1,2,4-OXADIAZOLES IN THE ABSENCE OF SOLVENT AND BASE.

1. INTRODUCTION (ARIAL, BOLD, 11 FONT, LEFT ALIGNED, CAPS)

The azoles are the five-membered heterocyclic compounds with two or three nitrogen atoms, constituting a large group of organic substances they have long been targeted for their use as therapeutic agents [1]. 1,2,4-oxadiazoles are a part of the azole family, containing two nitrogen atoms, two carbon and one oxygen atom in the ring. 1,2,4-oxadiazole containing these compounds have attracted great attention due to their applications in material chemistry and therapeutics [2]. The oxadiazole rings occur widely in biologically active synthetic compounds, and have often been used in the design of compounds with improved physicochemical properties and bioavailability, as they are a bioisosteres of esters and amides² and a dipeptide mimetic [3]. Compounds with a 1,2,4-oxadiazole nucleus have been suggested as muscarinic agonists [2,4], benzodiazepine agonists [5], dopamine ligands [6], antirhinovirals [2], growth hormone secretagogues [7], histamine H3 antagonists [8], inhibitors of the SH2 domain of tyrosine kinase [9], monoamine oxidase inhibitors [10], serotonergic (5-HT₃) antagonists [11], for their antitrypanosomal activity [12], as b-amyloid imaging agents in Alzheimer's disease [13], for their peptide inhibitory activity [14], for their antihyperglycemic activity [15] and as potential Combretastatin A-4 (CA-4) analogs [16].

They can act as anticonvulsant [17], anti-inflammatory [18,19], antimicrobial [20], antitumoral [21,22] properties as well as inhibitors of human neutrophil elastase [23], and human DNA topoisomerases [24]. More recently, publications have also shown their application in the field of luminescent liquid crystals, materials for optical devices, and as charge-transporters for organic light emitting diodes (OLEDs) [25,26].

In general, 1,2,4-oxadiazoles are synthesized in two steps by O-acylation of an amidoxime, which can be easily prepared by reaction of nitriles with hydroxylamine, with an activated carboxylic acid or derivatives (esters, anhydrides and acyl chloride), typically an active O-acylamidoxime, followed by cyclodehydration (Scheme 1) [27]. Another way to synthesize 1,2,4-oxadiazoles is based on the 1,3-cycloaddition of *N*-oxides to azomethines, nitriles, and iminoesters. Existing methods of synthesizing 1,2,4-oxadiazoles from carboxylic acid esters require the presence of strong bases, such as NaH or NaOEt, in refluxing THF or EtOH, and generally give low yields [28]. On the other hand, the condensation of carboxylic acid esters and amidoximes in the presence of potassium carbonate can be employed to synthesize a variety of mono-, bis- and tris-oxadiazoles in moderate to excellent yields [29]. In our research, we were interested in a user-friendly synthesis of 1,2,4-oxadiazoles with carboxylic acid esters and amidoximes with good yields.



R = R' = Alkyl or Aryl

X = -OR, -OCOR, -Cl

Scheme 1. Synthetic route for the preparation of 1,2,4-oxadiazoles.

Herein we report a favorable synthesis of 5- α -hydroxy-1,2,4-oxadiazoles and bis-oxadiazoles by heating of α -hydroxy esters and an amidoximes without any solvent and in the absence of a base. The synthesis is environmentally friendly.

2. MATERIAL AND METHODS / EXPERIMENTAL DETAILS / METHODOLOGY

Material

All commercially available reagents were used directly without purification unless otherwise stated. All the solvents used in reactions distilled for purity. Infrared spectra were recorded on a Bruker IFFS66 series Fourier transform spectrophotometer. NMR spectra were recorded with a Varian Unity Plus instrument (300/75 MHz for $^1\text{H}/^{13}\text{C}$) spectrometer, using CDCl_3 or DMSO as solvent and Me_4Si as the internal standard. Chemical shifts are reported in ppm. Coupling constants are reported in Hz. Thin Layer Chromatography (TLC) was performed using Merck Silica gel 60 F₂₅₄ Plates. Elemental analyses were carried out with a Carlo Erba model 1110 apparatus. The results of the elemental analysis (C, H, N) are within $\pm 0.4\%$ of the calculated amounts.

General experimental procedure for the synthesis of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles 5a-d

α -hydroxy esters (0.190g, 1.0 mmol) and amidoxime (0.214g, 5.0 mmol) were mixed in a vial. The mixture reaction was then heated in an oil bath at 105-110 °C for 4 h. TLC showed completion of the reaction. The resultant mixture was then purified by chromatography on silica gel to produce a pale yellow oil product in good and moderate yield.

General experimental procedure for the synthesis of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles 6a-d, 7a/d, 8a-d and 9a-c

α -hydroxy esters (0.206g, 1.0 mmol) and amidoxime (0.33g, 2.0 mmol) were mixed in a vial. The reaction mixture was then heated in an oil bath at 110-120 °C for 5 h when the mixture stopped reacting. Progress of the reaction was monitored by TLC, indicated completion of the reaction. The resultant mixture was then purified by chromatography on silica gel to give product as a white solid in moderate yield.

3-phenyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (5a): Pale yellow oil, yield 71%, R_f =0.62 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3415 (O-H), 2926 (C-H), 1593, 1352, 1129, 688 cm^{-1} ; ^1H NMR (CDCl_3): δ 8.13-8.04 (m, 2H, Ph-H), 7.53-7.44 (m, 3H, Ph-H), 5.16 (q, 1H, J = 6.6 Hz); 3.00 (s, 1H, O-H), 1.69 (d, 3H, J = 6.6 Hz); ^{13}C NMR (CDCl_3): δ 181.1, 168.1, 131.3, 128.9, 127.4, 126.2, 63.2, 21.3. Anal. Calcd for $\text{C}_{10}\text{H}_{10}\text{N}_2\text{O}_2$: C, 63.15; H, 4.30; N, 14.75. Found: C, 63.13; H, 5.25; N, 14.72.

3-*p*-tolyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (5b): Pale yellow oil, yield 73%, R_f =0.51 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3407 (O-H), 2917 (C-H), 1580, 1339, 1138, 727 cm^{-1} ; ^1H NMR (CDCl_3): δ 7.97 (d, 1H, J = 8.0 Hz Ph-H), 7.40 (m, 3H, Ph-H), 5.15 (q, 1H, J = 6.8 Hz), 2.40 (s, 1H, O-H), 1.67 (d, 3H, J = 6.8 Hz); ^{13}C NMR (CDCl_3): δ 180.6, 167.5, 141.2, 129.1, 126.9, 122.9, 62.6, 21.04, 21.02. Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_2$: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.62; H, 5.89; N, 13.71.

3-*m*-tolyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (5c): Pale yellow oil, yield 76%, R_f =0.53 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3394 (O-H), 2957 (C-H), 1569, 1338, 1115, 749 cm^{-1} ; ^1H NMR (CDCl_3): δ 7.86 (m, 2H, Ph-H), 7.35 (m, 2H, Ph-H), 5.18-5.11 (q, 1H, J = 6.6 Hz), 3.70 (s, 1H, O-H), 2.40 (s, 3H, $\text{H}_3\text{C-Ph}$), 1.71 (d, 3H, J = 6.6 Hz); ^{13}C NMR (CDCl_3): δ 188.5, 167.8, 138.3, 131.7, 128.4, 127.6, 125.7, 124.1, 62.9, 21.0, 21.0. Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_2$: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.63; H, 5.90; N, 13.69.

3-*o*-tolyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (5d): Pale yellow oil, yield 65%, R_f =0.56 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3289 (O-H), 2957 (C-H), 1580, 1339, 1112, 767 cm^{-1} ; ^1H NMR (CDCl_3): δ 7.96 (d, J =8.4 Hz, 1H, Ph-H), 7.35-7.23 (m, 3H, Ph-H), 5.25-5.20 (q, 1H, J = 6.9 Hz), 3.25 (s, 1H, O-H), 2.62 (s, 3H, $\text{H}_3\text{C-Ph}$), 1.72 (d, 3H, J = 6.6 Hz); ^{13}C NMR (CDCl_3): δ 180.2, 168.9, 138.6, 131.7, 131.0, 130.4, 126.3, 125.9, 63.6, 22.4, 21.7. Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{N}_2\text{O}_2$: C, 64.69; H, 5.92; N, 13.72. Found: C, 64.61; H, 5.91; N, 13.68.

1,2-bis-(3-phenyl-1,2,4-oxadiazol-5-yl)-ethanol (6a): Yield 55%; R_f =0.66 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3395, 1596, 1345, 1087, 726 cm^{-1} ; ^1H NMR (300MHz, CDCl_3) δ 7.90 (2H, m), 7.49 (3H, m), 5.51 (t, 1H, J = 4.5 Hz), 4.24 (bs, 1H), 3.52 (d, 2H, J =4.5 Hz); ^{13}C NMR (75MHz, CDCl_3) δ 177.5, 175.3, 168.1, 167.8, 131.2, 128.6, 127.1, 125.8, 63.9, 31.9. Anal. Calcd for $\text{C}_{18}\text{H}_{14}\text{N}_4\text{O}_3$: C, 64.66; H, 4.22; N, 16.76. Found: C, 64.63; H, 4.21; N, 16.74.

1,2-bis-(3-*p*-tolyl-1,2,4-oxadiazol-5-yl)-ethanol (6b): Yield 68%; R_f =0.76 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3303, 1650, 1353, 1075, 738 cm^{-1} ; ^1H NMR (300MHz, CDCl_3) δ 7.88 (4H, m), 7.24 (4H, m), 5.51 (t, 1H, J = 6.0 Hz), 3.63 (d, 2H, J = 6.0 Hz), 2.41 (s, 6H); ^{13}C NMR (75MHz, CDCl_3) δ 178.0, 175.8, 168.8, 168.5, 142.3, 130.0, 127.8, 123.6, 64.6, 32.6, 22.0. Anal. Calcd for $\text{C}_{20}\text{H}_{18}\text{N}_4\text{O}_3$: C, 66.29; H, 5.01; N, 15.46. Found: C, 66.31; H, 4.99; N, 15.44.

1,2-bis-(3-*m*-tolyl-1,2,4-oxadiazol-5-yl)-ethanol (6c): Yield 65%; R_f =0.71 (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3367, 1575, 1451, 1125, 763 cm^{-1} ; ^1H NMR (300MHz, CDCl_3) δ 7.85 (2H, m), 7.27 (2H, m), 5.53 (t, 1H, J = 6.0 Hz), 4.72 (bs, 1H), 3.74 (d, 2H, J = 6.0 Hz), 2.43 (s, 3H); ^{13}C NMR (75MHz, CDCl_3) δ 177.4, 175.2, 168.2, 167.9, 138.4,

131.9, 128.5, 127.7, 125.7, 125.0, 124.3, 63.9, 31.9, 20.9. Anal. Calcd for $C_{20}H_{18}N_4O_3$: C, 66.29; H, 5.01; N, 15.46. Found: C, 66.28; H, 5.02; N, 15.43.

1,2-bis-(3-*o*-tolyl-1,2,4-oxadiazol-5-yl)-ethanol (6d): Yield 51%; $R_f=0.72$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3350, 1577, 1362, 1103, 721 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 7.77 (2H, m), 7.26 (2H, m), 5.52 (t, 1H, $J = 6.0$ Hz), 3.56 (d, 2H, $J = 6.0$ Hz), 2.42 (s, 3H); ^{13}C NMR (75MHz, $CDCl_3$) δ 177.3, 175.1, 168.0, 167.8, 138.3, 131.8, 128.4, 127.6, 125.4, 124.2, 63.8, 31.8, 20.9. Anal. Calcd for $C_{20}H_{18}N_4O_3$: C, 66.29; H, 5.01; N, 15.46. Found: C, 66.32; H, 5.00; N, 15.47.

1,2-bis-(3-phenyl-1,2,4-oxadiazol-5-yl)-ethane-1,2-diol (7a): Yield 56%; $R_f=0.71$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3350, 1577, 1362, 1103, 721 cm^{-1} ; 1H NMR (300MHz, $DMSO-d_6$) δ 8.00 (2H, m), 7.54 (3H, m), 6.95 (s, 1H, CH), 5.50 (s, 1H, CH); ^{13}C NMR (75MHz, $DMSO-d_6$) δ 178.7, 167.7, 131.8, 129.5, 127.2, 126.2, 69.2, 68.2. Anal. Calcd for $C_{18}H_{14}N_4O_4$: C, 61.71; H, 4.03; N, 15.99. Found: C, 61.69; H, 4.01; N, 15.97.

1,2-bis-(3-*o*-tolyl-1,2,4-oxadiazol-5-yl)-ethane-1,2-diol (7d): Yield 37%; $R_f=0.67$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3350, 1577, 1362, 1103, 721 cm^{-1} ; 1H NMR (300MHz, $DMSO-d_6$) δ 7.77 (2H, m), 7.48 (2H, m), 6.76 (s, 1H, CH), 5.50 (s, 1H, CH), 2.44 (s, 3H); ^{13}C NMR (75MHz, $DMSO-d_6$) δ 178.0, 167.3, 138.4, 131.9, 128.8, 127.1, 126.3, 123.9, 68.7, 20.52. Anal. Calcd for $C_{20}H_{18}N_4O_4$: C, 63.48; H, 4.78; N, 14.81. Found: C, 63.49; H, 4.77; N, 14.82.

Methyl 3-hydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)-propanoate (8a): Yield 30%; $R_f=0.45$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3395, 1752, 1597, 1344, 1089, 726 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 8.04 (2H, m), 7.50 (3H, m), 5.48 (s, 1H), 3.76 (s, 3H), 3.06 (m, 2H, $J = 6.3$ Hz), 1.54 (s, 1H); ^{13}C NMR (75MHz, $CDCl_3$) δ 180.1, 169.8, 167.2, 131.4, 129.1, 126.7, 125.8, 61.9, 51.4, 21.5. Anal. Calcd for $C_{12}H_{12}N_2O_4$: C, 58.06; H, 4.87; N, 11.29. Found: C, 58.04; H, 4.89; N, 11.27.

Methyl 3-hydroxy-3-(3-*p*-tolyl-1,2,4-oxadiazol-5-yl)-propanoate (8b): Yield 33%; $R_f=0.50$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3404, 1752, 1595, 1446, 1361, 1048, 758 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 8.00 (2H, m), 7.42 (3H, m), 5.49 (t, 1H, $J = 5.1$ Hz), 3.76 (s, 3H), 3.04 (m, 2H, $J=5.1$ Hz), 2.48 (s, 3H); ^{13}C NMR (75MHz, $CDCl_3$) δ 177.9, 170.8, 167.9, 141.3, 129.1, 127.0, 123.0, 63.3, 51.9, 38.4, 21.1. Anal. Calcd for $C_{13}H_{14}N_2O_4$: C, 59.54; H, 5.38; N, 10.68. Found: C, 59.52; H, 5.37; N, 10.69.

Methyl 3-hydroxy-3-(3-*m*-tolyl-1,2,4-oxadiazol-5-yl)-propanoate (8c): Yield 33%; $R_f=0.51$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3242, 1734, 1570, 1450, 1340, 1037, 716 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 7.88 (2H, m), 7.44 (2H, m), 5.48 (t, 1H, $J = 3.6$ Hz), 3.75 (s, 3H), 3.04 (m, 2H, $J=5.1$ Hz), 2.48 (s, 3H); ^{13}C NMR (75MHz, $DMSO-d_6$) δ 178.1, 170.9, 168.1, 138.4, 131.9, 128.4, 127.8, 125.9, 124.3, 63.4, 52.0, 38.6, 20.9. Anal. Calcd for $C_{13}H_{14}N_2O_4$: C, 59.54; H, 5.38; N, 10.68. Found: C, 59.55; H, 5.39; N, 10.67.

Methyl 3-hydroxy-3-(3-*o*-tolyl-1,2,4-oxadiazol-5-yl)-propanoate (8d): Yield 16%; $R_f=0.50$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3406, 1738, 1595, 1476, 1337, 1048, 751 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 7.96 (2H, d, $J = 8.4$ Hz), 7.44 (2H, m, $J = 8.4$ Hz), 5.48 (t, 1H, $J = 5.1$ Hz), 3.75 (s, 3H), 3.04 (m, 2H, $J = 4.8$ Hz), 2.48 (s, 3H); ^{13}C NMR (75MHz, $CDCl_3$) δ 180.5, 170.3, 167.8, 166.4, 139.0, 132.6, 129.5, 127.7, 126.2, 124.5, 62.5, 51.9, 30.3, 21.2. Anal. Calcd for $C_{13}H_{14}N_2O_4$: C, 59.54; H, 5.38; N, 10.68. Found: C, 59.53; H, 5.36; N, 10.69.

Ethyl 2,3-dihydroxy-3-(3-phenyl-1,2,4-oxadiazol-5-yl)-propanoate (9a): Yield 16%; $R_f=0.40$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3392, 1742, 1570, 1446, 1368, 1089, 706 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 8.00 (m, 2H), 7.48 (2H, m), 5.42 (d, 1H, $J = 1.8$ Hz), 4.74 (d, 1H, $J = 1.8$ Hz), 4.25 (m, 2H, $J = 5.4$ Hz), 3.75 (s, 2H), 1.25 (m, 3H, $J = 5.4$ Hz); ^{13}C NMR (75MHz, $CDCl_3$) δ 171.5, 170.9, 168.3, 131.4, 128.9, 127.6, 126.2, 72.3, 68.7, 63.0, 14.1. Anal. Calcd for $C_{13}H_{14}N_2O_5$: C, 56.11; H, 5.07; N, 10.07. Found: C, 56.10; H, 5.06; N, 10.08.

Ethyl 2,3-dihydroxy-3-(3-*p*-tolyl-1,2,4-oxadiazol-5-yl)-propanoate (9b): Yield 31%; $R_f=0.32$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3357, 1737, 1581, 1456, 1353, 1080, 729 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 7.98 (m, 2H), 7.26 (2H, m), 5.42 (d, 1H, $J = 2.4$ Hz), 4.68 (d, 1H, $J = 2.4$ Hz), 4.25 (m, 2H, $J = 6.9$ Hz), 3.24 (s, 2H), 2.44 (s, 3H), 1.25 (m, 3H, $J = 6.9$ Hz); ^{13}C NMR (75MHz, $DMSO-d_6$) δ 177.5, 171.9, 171.3, 142.1, 129.9, 127.8, 123.7, 72.3, 69.0, 62.8, 21.9, 14.4. Anal. Calcd for $C_{13}H_{14}N_2O_5$: C, 56.11; H, 5.07; N, 10.07. Found: C, 56.12; H, 5.08; N, 10.06.


Ethyl 2,3-dihydroxy-3-(3-*m*-tolyl-1,2,4-oxadiazol-5-yl)-propanoate (9c): Yield 28%; $R_f=0.41$ (dichloromethane–ethyl acetate, 9:1); IR ν_{max} (KBr): 3356, 1742, 1570, 1446, 1368, 1089, 706 cm^{-1} ; 1H NMR (300MHz, $CDCl_3$) δ 7.86 (m, 2H), 7.25 (2H, m), 5.50 (d, 1H, $J = 1.8$ Hz), 4.72 (d, 1H, $J = 1.8$ Hz), 4.33 (m, 2H, $J = 5.1$ Hz), 3.50 (s, 2H), 2.30 (s, 3H), 1.23 (m, 3H, $J = 5.1$ Hz); ^{13}C NMR (75MHz, $CDCl_3$) δ 177.3, 171.6, 170.9, 168.3, 138.7, 132.3, 128.8, 128.1, 126.0, 124.7, 72.0, 68.9, 62.5, 21.2, 14.1. Anal. Calcd for $C_{13}H_{14}N_2O_5$: C, 56.11; H, 5.07; N, 10.07. Found: C, 56.09; H, 5.07; N, 10.06.

In silico study of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles 6a-d, 7a/d, 8a-d and 9a-c

The values of consensus Log Po/w(cLogP), molecular weight (MW), N° H-bond acceptors (nHBA), N° H-bond donors (nHBD), N° of violations of Lipinski's rule, gastrointestinal absorption, and blood-brain barrier permeant were calculated using Swiss ADME provided by the Swiss Institute of Bioinformatics.

3. RESULTS AND DISCUSSION


The precursors arylamidoximes **1a-d** could be easily synthesized with moderate and excellent yields (31- 89%) by reaction of nitrile and hydroxylamine hydrochloride in water at 25°C [30, 31]. The general synthetic strategy for the synthesis of 1,2,4-oxadiazoles and bis-1,2,4-oxadiazoles is illustrated in Scheme 2.



Scheme 2. Synthesis of 1,2,4-oxadiazoles from amidoximes and carboxylic acid esters.

The 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles were synthesized by treatment of arylamidoxime **1a-d** with α -hydroxy esters for 4 hours without any solvent and in the absence of a base. The reaction was monitored by thin layer chromatography (TLC). The heterocycles **5a-d**, **6a-d**, **7a/d**, **8a-d** and **9a-c** were obtained in moderate and good yields (16-76%). As shown in Scheme 2, the condensation of carboxylic acid esters with amidoximes under simple and solvent-free conditions yielded bis-oxadiazoles (**6a-d** and **7a/d**) and 1,2,4-oxadiazoles **5a-d**, **8a-d** and **9a-c**.

The scope and generality of this process is illustrated by a series of seventeen compounds and the results are presented in Table 1 below. Based on these data, we proposed the following mechanism for the formation of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles (**5a-d**, **6a-d** and **7a/d**).




















Scheme 3. Plausible mechanism for the formation of 1,2,4-oxadiazoles.

The oxygen of the amidoxime then performs nucleophilic attack on the ester carbonyl, to furnish an unstable tetrahedral species (III and IV) with subsequent loss of alcohol to give V. Upon restoration of the double bond, C = O (V) is the output of alcohol formation of carbonic acid and O-acylated amidoxime (VI), which, in turn, undergo intramolecular nucleophilic attack for the formation of intermediate (VII). At high temperatures there is an output of a molecule of water and formation of the double bond between N-4 and C-5 and therefore of the 1,2,4-oxadiazole ring.

We found the reaction presented an ample scope of applications furnishing the desired products in moderate to good yield (Table 1). We observed that arylamidoximes containing methyl group attached to the meta and para position react similarly, while ortho tolylamidoxime undergoes a reaction furnished a minor yield of the product (16-55%) probably due to the steric hindrance. The presences of electron-withdrawing and electron-donating groups attached to the para position of arylamidoximes were well tolerated by the reaction.

Table 1. Synthesis 1,2,4-oxadiazole derivatives **5a-d**, **8a-d**, **9a-c** and bis-1,2,4-oxadiazoles **6a-d**, **7a/d**.

Entry	α -hydroxy esters	Amidoximes	Products	Yield (%)
1	2	1a	 5a	71
2	2	1b	 5b	73
3	2	1c	 5c	76
4	2	1d	 5d	65
5	3	1a	 6a	55
6	3	1b	 6b	68
7	3	1c	 6c	65
8	3	1d	 6a	51
9	4	1a	 7a	56
10	4	1d	 7d	37
11	3	1a		30

				
12	3	1b		20
13	3	1c		25
14	3	1d		33
15	4	1a		16
16	4	1b		28
17	4	1c		31

The products were characterized by IR, ^1H and ^{13}C NMR spectroscopy and all compounds were in full agreement with the proposed structure. For instance, IR absorptions at 1593 ($\text{C}=\text{N}$) and 1473 cm^{-1} ($\text{C}-\text{O}$) were obtained for 3-phenyl-5-(1-hydroxyethyl)-1,2,4-oxadiazoles (**5a**). ^1H NMR spectra showed absorption of methine proton of $\text{C}-\text{OH}$ at δ 5.16. Signals of the methyl groups for **5a-d** appeared as doublets at 1.69 ppm ($J = 6.6$ Hz). The characteristic signals for NCO and NCN in ^{13}C NMR at 180.9 and 168.1 ppm further identified oxadiazole moiety in **5a**. With respect to compounds **6a-d** the ^1H NMR spectra showed a triplet at 5.33 ppm ($J = 4.5$ Hz) for methine proton and a doublet at 3.71 ppm ($J = 4.5$ Hz) for the methylene groups. The compounds **8a-d** showed a singlet at 3.76 ppm due to methyl groups of ester groups. Signals of the CH protons for **7a-d** appeared as singlet at 6.93 and 5.50 ppm. All other proton signals are observed in their usual resonance areas. On the other hand, the compounds **8a-d** showed a singlet at 3.76 ppm due to methyl groups of ester groups.

The synthesis of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles (**5a-d**, **6a-d**, **7a/d**, **8a-d** and **9a-c**) may become very useful source for the researchers, since that the *in silico* study of these compounds indicated interesting pharmacokinetic, toxicological and chemical characteristics that make future research viable (Table 2).

Table 2. *In silico* study of the pharmacokinetic, toxicological and chemical properties of the 1,2,4-oxadiazole derivatives **5a-d**, **8a-d**, **9a-c** and bis-1,2,4-oxadiazoles **6a-d**, **7a/d**.

Entry	ClogP	MW	nHBA	nHBD	Lipinski	Chronic Toxicity
1	1.58	190.20	4	1	0	Low risk
2	1.90	204.23	4	1	0	Low risk
3	1.86	204.23	4	1	0	Low risk
4	1.86	204.23	4	1	0	Low risk
5	2.69	334.33	7	1	0	Low risk
6	3.42	362.38	7	1	0	Low risk
7	3.45	362.38	7	1	0	Low risk
8	3.31	362.38	7	1	0	Low risk
9	1.89	350.33	8	2	0	Low risk
10	2.64	378.38	8	2	0	Low risk
11	1.27	248.23	6	1	0	Low risk
12	1.61	262.26	6	1	0	Low risk
13	1.60	262.26	6	1	0	Low risk
14	1.59	262.26	6	1	0	Low risk
15	0.84	278.26	7	2	0	Low risk
16	1.21	292.29	7	2	0	Low risk
17	1.20	292.29	7	2	0	Low risk

Subtitle: cLogP: Consensus Log Po/w; MW: Molecular weight; nHBD: N° H-bond donors; nHBA: N° H-bond acceptors; Lipinski: N° of violations of Lipinski's rule

According to table 2, it was possible to observe that all analyzed compounds present cLogP lower than 5, thus indicating a good absorption pattern [32]. When evaluating the physicochemical properties of different drugs, Lipinski's group observed that compounds with good oral absorption had a common molecular mass (MW) of less than 500 Daltons, a partition coefficient (cLogP) of less than 5, a maximum of five hydrogen bond donor groups (nHBD) and a maximum of ten hydrogen bond acceptor groups (nHBA) [33]. Thus, all analyzed compounds fit the parameters determined by the "Rule of 5", expressing favorable potential for oral absorption of these compounds and corroborating the good pharmacokinetic characteristics indicated by the cLogP analysis (Table 2).

The estimated toxicity of the synthesized compounds was evaluated, especially their potential to develop effects of chronic toxicity, namely, mutagenicity, tumorigenicity, irritant and interfering with human reproduction [34]. As observed in Table 2, molecular fragments were found for these compounds' indicative of low risk of chronic toxicity, especially irritant, tumorigenic and mutagenic activity. The chronic toxicity potential of these compounds, especially their genotoxic,

mutagenic and tumorigenic effects, has been widely debated, with studies in the literature demonstrating this property for these compounds [35, 36], justifying the result obtained in in silico analysis. Additionally, compounds containing this oxadiazole nucleus are reported to have a wide range of pharmaceutical and biological applications including anti-inflammatory and analgesic activities [1, 14-16]. Future research should also evaluate possible activities of these compounds and their derivatives as likely therapeutic agents.

4. CONCLUSION

In summary, we report here on a convenient synthesis of 3-aryl-5-hydroxyalkyl-1,2,4-oxadiazoles from readily available α -hydroxy esters and arylamidoximes without any solvent and in the absence of a base. The final products were obtained after four hours in moderate to good yields. *In silico* study they have shown promising properties for the synthesized oxadiazoles, pointing out the high probability of these molecules being well absorbed after an oral administration and presenting a low risk of chronic toxicity. These results stimulate further research in the field of synthetic chemistry and medicinal chemistry.

ACKNOWLEDGEMENTS

The authors are grateful to the Brazilian National Research Council (CNPq), FACEPE (APQ-0303-1.06/16 and APQ 1037-1.06/2021) and Coordination for the Improvement of Higher Education Staff (CAPES) for financial support.

COMPETING INTERESTS

The authors declare no conflict of interest.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Arshad M, Khan TA, Khan MA. 1,2,4-Oxadiazole Nucleus With Versatile Biological Applications *Int. J. Pharm Sci. Res.* 2014, 5, 303-17.
2. Diana GD, Volkots DL, Nitz TJ, Baily TR, Long MA, Vescio N, Aldous S, Pevear DC, Dutko FJ. Oxadiazoles as Ester Bioisosteric Replacements in Compounds Related to Disoxaril. *Antirhinovirus Activity J. Med. Chem.* 1994, 37, 2421-36.
3. Borg S, Vollinga RC, Labarre M, Payza K, Terenius L, Luthman K. Design, Synthesis, and Evaluation of Phe-Gly Mimetics: Heterocyclic Building Blocks for Pseudopeptides. *J. Med. Chem.* 1999, 42, 4331-42.
4. Andersen KE, Jørgensen AS, Bræstrup C. Oxadiazoles as bioisosteric transformations of carboxylic functionalities. Part I *Eur. J. Med. Chem.* 1994, 29, 393-399.
5. Watjen F, Baker R, Engelstoff M, Herbert R, MacLeod A, Knight A, Merchant K, Moseley J, Saunders J, Swain C, Wong E, Springer JP. Novel benzodiazepine receptor partial agonists: oxadiazolyimidazobenzodiazepines. *J. Med. Chem.* 1989, 32, 2282-2291.

291 6. Carrol FI, Gray JL, Abraham P, Kuzemko MA, Lewin AH, Boja JW, Kuhar MJ. 3-Aryl-2-(3'-substituted-1',2',4'-oxadiazol-
292 5'-yl)-tropane analogs of cocaine: affinities at the cocaine binding site at the dopamine, serotonin, and norepinephrine
293 transporters *J. Med. Chem.* 1993, 36, 2886-2890.

294 7. Ankersen M, Peschke B, Hansen BS, Hansen TK. Investigation of bioisosters of the growth hormone secretagogue I-
295 692,429. *Bioorg. Med. Chem. Lett.* 1997, 7, 1293-1298.

296 8. Vu CB, Corpuz EG, Merry TJ, Pradeepan SG, Bartlett C, Bohacek RS, Botfield MC, Eyermann CJ, Lynch BA, MacNeil
297 IA, Ram MK, van Schravendijk MR, Violette S, Sawyer T K. Discovery of Potent and Selective SH2 Inhibitors of the
298 Tyrosine Kinase ZAP-70. *J. Med. Chem.* 1999, 42, 4088-4098.

299 9. Buchanan JL, Vu CB, Merry TJ, Corpuz EG, Pradeepan SG, Mani UN, Yang M, Plake H R, Varkhedkar VM, Lynch BA,
300 MacNeil IA, Loiacono KA, Tiong CL, Holt D A. Structure-activity relationships of a novel class of Src SH2 inhibitors.
301 *Bioorg. Med. Chem. Lett.* 1999, 9, 2359-2364.

302 10. Matsumoto J, Takahashi T, Agata M, Toyofuku H, Sasada N. A study of the biological pharmacology of IFO, a new
303 selective and reversible monoamine oxidase-B inhibitor. *Jpn. J. Pharmacol.* 1994, 65, 51-57.

304 11. Chen C, Senanayake CH, Bill TJ, Larsen RD, Verhoeven TR, Reider PJ. Improved Fischer Indole Reaction for the
305 Preparation of N,N-Dimethyltryptamines: Synthesis of L-695,894, a Potent 5-HT_{1D} Receptor Agonist. *J. Org. Chem.*
306 1994, 59, 3738-3741.

307 12. Filho JMS, Leite ACL, Oliveira BG, Moreira DRM, Lima MS, Soares MBP, Leite LFC. Design, synthesis and cruzain
308 docking of 3-(4-substituted-aryl)-1,2,4-oxadiazole-N-acylhydrazones as anti-Trypanosoma cruzi agents. *Bioorg. Med.*
309 *Chem.* 2009, 17, 6682-6691.

310 13. Ono M, Haratake M, Saji H, Nakayama M. Development of novel β -amyloid probes based on 3,5-diphenyl-1,2,4-
311 oxadiazole. *Bioorg. Med. Chem.* 2008, 17, 6867-6872.

312 14. Borg S, Luthman K, Nyberg F, Terenius L, Hacksell U. 1,2,4-Oxadiazole derivatives of phenylalanine: potential
313 inhibitors of substance P endopeptidase. *Eur. J. Med. Chem.* 1993, 28, 801-810.

314 15. Malamas MS, Sredy J, McCaleb M, Gunawan I, Mihan B, Sullivan D. Antihyperglycemic activity of new 1,2,4-
315 oxadiazolidine-3,5-diones. *Eur. J. Med. Chem.* 2001, 36, 31-42.

316 16. Das BC, Tang X, Rogler P, Evans T. Design and synthesis of 3,5-disubstituted boron-containing 1,2,4-oxadiazoles as
317 potential combretastatin A-4 (CA-4) analogs. *Tetrahedron Lett.* 2012, 53, 3947-3950.

318 17. Mohammadi-Khanaposhtani M, Shabani M, Faizi M, Aghaei I, Jahani R, Sharafi Z, Zafarghandi NS, Mahdavi M,
319 Akbarzadeh T, Emami S, Shafiee A, Foroumadi A. Design, synthesis, pharmacological evaluation, and docking study of
320 new acridone-based 1,2,4-oxadiazoles as potential anticonvulsant agentes. *Eur. J. Med. Chem.* 2016, 112, 91-98.

321 18. Bora RO, Dar B., Pradhan V, Farooqui M. 1, 2, 4-oxadiazoles: synthesis and biological applicatios. *Mini-reviews in*
322 *Medicinal Chemistry*, 2014;14 (4), 355-369.

323 19. Gobec M, Tomašič T, Markovič T, Mlinarič-Raščan I, Dolenc MS, Jakopin Ž. Antioxidant and anti-inflammatory
324 properties of 1,2,4-oxadiazole analogs of resveratrol. *Chem Biol Interact.* 2015; 240:200-7.

325 20. Biernacki K, Dásko M, Ciupak O, Kubinsk K, Rachon J, Demkowicz S. Novel 1,2,4-Oxadiazole Derivatives in Drug
326 Discovery. *Pharmaceutics*, 2020, 13, 6, 1-45.

327 21. Maftai CV, Fodor E, Jones PG, Franz MH, Kelter G, Fiebig H, Neda, I. Synthesis and characterization of novel
328 bioactive 1,2,4-oxadiazole natural product analogs bearing the N-phenylmaleimide and N-phenylsuccinimide moieties.
329 *Beilstein J. Org. Chem.* 2013, 9, 2202–2215.

330 22. Moniot S, Forgione M, Lucidi A, Hailu GS, Nebbioso A, Carafa V, Baratta F, Altucci L, Giacché N, Passeri D,
331 Pellicciari R, Mai A, Steegborn C, Dante Rotili, D. Development of 1,2,4-oxadiazoles as potent and selective inhibitors of
332 the human deacetylase sirtuin 2: structure-activity relationship, X-ray crystal structure, and anticancer activity, *Journal of*
333 *Medicinal Chemistry*, 2017, 60, 6, 2344–2360.

23. Ohmoto K, Yamamoto T, Horiuchi T, Imanishi H, Odagaki Y, Kawabata K, Sekioka T, Hirota Y, Matsuoka S, Nakai H, Toda M. Design and synthesis of new orally active nonpeptidic inhibitors of human neutrophil elastase. *J. Med. Chem.* 2000, 43, 4927-4929.
24. Rudolph J, Theis H, Hanke R, Endermann R, Johannsen L, Geschke F.-U. seco-Cyclothialidines: New Concise Synthesis, Inhibitory Activity toward Bacterial and Human DNA Topoisomerases, and Antibacterial Properties. *J. Med. Chem.* 2001, 44, 619-626.
25. Subrao M, Potukuchi DM, Ramachandra GS, Bhagavath P, Bhat SG, Maddasani S. Novel biphenyl-substituted 1,2,4-oxadiazole ferroelectric liquid crystals: synthesis and characterization. *Beilstein J. Org. Chem.* 2015, 11, 233-241.
26. Filho RAWN, Bezerra NMM, Guedes JM, Srivastava RM. An easy synthesis of 3,5-disubstituted 1,2,4-oxadiazoles from carboxylic acids and arylamidoximes mediated by ethyl chloroformate. *J. Braz. Chem. Soc.* 2009, 20, 1365-1369.
27. Chiou S, Shine HJ. A simplified procedure for preparing 3,5-disubstituted-1,2,4-oxadiazoles by reaction of amidoximes with Acyl chlorides in pyridine solution. *J. Heterocyclic Chem.* 1989, 26, 125-128.
28. Kayukova L.A. Synthesis of 1,2,4-oxadiazoles (a review). *Pharm. Chem. J.* 2005, 39, 539-547.
29. Amarasinghe KD, Maier MB, Srivastava A, Gray JL. One-pot synthesis of 1,2,4-oxadiazoles from carboxylic acid esters and amidoximes using potassium carbonate. *Tetrahedron Lett.* 2006, 47, 3629-3631.
30. Srivastava RM, Pereira MC, Faustino WWM, Coutinho K, dos Anjos JV, de Melo SJ. Synthesis, mechanism of formation, and molecular orbital calculations of arylamidoximes. *Monatsh Chem.* 2009, 140, 1319-1324.
31. Barros CJP, Freitas JJR, Freitas Filho JR, Oliveira RN. Synthesis of amidoximes using an efficient and rapid ultrasound method. *J. Chil. Chem. Soc.*, 2011, 56, 721-722.
32. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv. Drug Deliv. Rev.*, 1997, 23, 4-25.
33. Lipinski CA. Lead and drug-like compounds: the rule-of-five revolution. *Drug Discov. Today Technol.*, 2004, 1, 337-341.
34. Daina A, Michielin O, Zoete V. Swiss ADME: a free web tool to evaluate pharmacokinetics, druglikeness and medicinal chemistry friendliness of small molecules. *Sci. Rep.*, 2017, 7, 1, 1-13.
35. Maslat AO, Abussaud M, Tashtoush H, AL-Talib M. Synthesis, antibacterial, antifungal and genotoxic activity of bis-1,3,4-oxadiazole derivatives. *Pol. J. Pharmacol.*, 2002, 54, 55-59.
36. Ibrahimab TS, Almalkia AJ, Moustafac AH, Allamd RM, Abuo-Rahmaef GEDA, Subbaghg HIE, Mohamedh MFA. Novel 1,2,4-oxadiazole-chalcone/oxime hybrids as potential antibacterial DNA gyrase inhibitors: Design, synthesis, ADMET prediction and molecular docking study. *Bioorg. Chem.*, 2021, 111, 104885.